A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

September 4, 2026

Study Completion Date

September 4, 2026

Conditions
Mesothelioma
Interventions
DRUG

IAG933

Capsule

Trial Locations (16)

3000

Novartis Investigative Site, Melbourne

8091

Novartis Investigative Site, Zurich

20089

Novartis Investigative Site, Rozzano

20133

Novartis Investigative Site, Milan

44195

Cleveland Clinic Foundation, Cleveland

45147

Novartis Investigative Site, Essen

60637

Uni of Chi Medi Ctr Hema and Onco, Chicago

90095

University of California LA, Los Angeles

94800

Novartis Investigative Site, Villejuif

02114

Massachusetts General Hospital, Boston

77030 4009

MD Anderson Cancer Center, Houston

H2W 1T8

Novartis Investigative Site, Montreal

104 0045

Novartis Investigative Site, Chuo Ku

3015 GD

Novartis Investigative Site, Rotterdam

08035

Novartis Investigative Site, Barcelona

M20 2BX

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY